Sarepta Therapeutics ( NASDAQ:SRPT – Get Free Report ) ‘s stock had its 'overweight' rating reissued by research analysts at Morgan Stanley in a research note issued on Friday, Benzinga reports. They presently have a $183.00 price objective on the biotechnology company's stock. Morgan Stanley's target price would suggest a potential upside of 69.44% from the stock's current price. Other equities research analysts have also issued reports about the company. UBS Group upped their price target on Sarepta Therapeutics from $160.

https://www.dailypolitical.com/2023/07/14/sarepta-therapeutics-nasdaqsrpt-given-overweight-rating-at-morgan-stanley.html

#dailypolitical